But this pivot to THC is even more bold
The figures below come from separate trials in different populations, so cross-trial comparisons should be interpreted with caution
Now, before I lose you, let me hook you with this graph: In a double-blind, placebo-controlled 26-week study, patients given tesamorelin saw about a 15% reduction in visceral fat, while the placebo group actually trended upward (A)
It covers Wegovy and Zepbound (and similar medications) as a treatment for other obesity-related medical conditions such as hypertension and sleep apnea but not for TRICARE For Life users, after an Aug
It is associated with a mild form of carnitine palmitoyl transferase I deficiency, putting homozygous individuals at risk for fasting hypoglycemia 9,10
Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities